Vijaya Diagnostic Centre Ltd. · NSE:VIJAYA
Vijaya Diagnostic Centre — Q4 FY26 Earnings Presentation
48 slides from Vijaya Diagnostic Centre's earnings presentation, May 7, 2026
Slide 1: Exchange cover letter: Investor Presentation
May 07, 2026 To To The Listing Department, The Corporate Relations Department, National Stock Exchange of India Limited BSE Limited NSE Symbol: VIJAYA BSE Scrip Code: 543350 Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requiremen
Slide 2: Q4 & 12M FY26 Earnings Presentation
Q4 & 12M FY26 Earnings Presentation May 7, 2026 Q2 & H1 FY25 Earnings Presentation, November 07, 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for
Slide 4: Disclaimer: Merger Note
Merger Note Disclaimer Note 1: Merger (Medinova Diagnostic Services Limited, Kolkata) : Pursuant to the NCLT, Hyderabad Bench order dated 13 October 2025, Medinova Diagnostic Services Limited got merged with the Company effective 01 April 2024. Accordingly, the financial numbers for the current peri
Slide 5: Q4 FY26 Performance Snapshot
Q4 FY26 Performance Snapshot Strategic Expansion
Slide 6: Q4 FY26 Performance Snapshot
Q4 FY26 Performance Snapshot Financial Performance Key Metrics 1.21 Mn 4.49 Mn INR 2,194 Mn Footfall Tests Revenue from Operations INR 955 Mn | 43.5% INR 479 Mn | 21.8% 162 (1) 92% EBITDA | EBITDA Margin % PAT | PAT Margin % Centres B2C Revenue % YOY Growth % Geographical Contribution Wellness Share
Slide 7: FY26 Performance Snapshot
FY26 Performance Snapshot Financial Performance Key Metrics 4.68 Mn 16.92 Mn INR 8,142 Mn Footfall Tests Revenue from Operations INR 3,369 Mn | 41.4% INR 1,730 Mn | 21.2% 162 (1) 92% EBITDA | EBITDA Margin % PAT | PAT Margin % Centres B2C Revenue % YOY Growth % Geographical Contribution Wellness Sha
Slide 8: Management Commentary
Management Commentary “ FY26 was a landmark year for Vijaya, as revenues crossed INR 800 Cr, translating into a 16.5% CAGR over the five years since listing, outperforming our long-term guidance of 15%. EBITDA margins also remained ahead of our 40% guidance, reflecting disciplined execution. Over th
Slide 9: Key Financial Highlights – Q4 FY26 & 12M FY26
Key Financial Highlights – Q4 FY26 & 12M FY26 Revenue from Operations (INR Mn) EBITDA & EBITDA Margin % PAT & PAT Margin % 39.8% 41.9% 43.5% 40.1% 41.4% 20.1% 21.0% 21.8% 21.1% 21.2% 8,142 6,814 3,369 2,732 1,730 Key 1,438 Financials 2,052 2,194 1,732 861 955 432 479 689 349 Q4 FY25 Q3 FY26 Q4 FY26
Slide 10: Key Operational Highlights
Key Operational Highlights Tests Performed (# in Mn) Footfalls (# in Mn) Tests / Footfalls (#) 4.68 16.92 4.19 3.70 14.79 3.62 3.61 3.62 3.53 4.22 4.49 1.05 1.17 1.21 3.79 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q3 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Revenue per Test (INR) Rev
Slide 11: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement (INR Mn) Particulars Q4 FY26 Q4 FY25 Y-o-Y Q3 FY26 Q-o-Q FY26 FY25 Y-o-Y Revenue from operations 2,193.8 1,732.4 26.6% 2,052.1 6.9% 8,142.0 6,813.9 19.5% Cost of materials consumed 249.3 221.7 12.5% 240.3 3.8% 946.8 847.6 11.7% Gross Profit 1,944.5 1,510.8 28.7%
Slide 12: Sustained Momentum Observed Across the Wellness Segment
Sustained Momentum Observed Across the Wellness Segment High Volume of Wellness testing being observed in younger 1 population due to increased awareness & growing chronic disease burden due to stress, sedentary life & shift in lifestyle patterns Adoption of wellness testing is scaling across market
Slide 13: Key Developments
Key Developments Strategic Expansion
Slide 14: Leveraging Technology for Scalable Growth
Leveraging Technology for Scalable Growth New CRM – xxEnabling 360° Transforming Operations through AI-Driven Solutions Elevating Relationship Management new ERP Diagnostic Excellence ➢ Intelligent lead & engagement ➢ Integration of finance, ➢ AI-Enabled Radiology workflows with personalized procure
Slide 15: Leveraging the Transformative Power of AI for CT KUB Cases Reporting
Leveraging the Transformative Power of AI for CT KUB Cases Reporting Automated Stone Detection & Intelligent Differentiation 3D Localization ▪ Auto-locates & measures ▪ Distinguishes true kidney stones stones from harmless pelvic vein calcifications and ▪ Precise 3D localization of vascular spots in
Slide 16: AI-Powered Dental Diagnostics for Precision Care
AI-Powered Dental Diagnostics for Precision Care ➢ AI dental diagnostics platform delivers high-precision 2D/3D radiograph analysis, predictive care, and clinical decision support ➢ Al-based 2D & CBCT scan analysis for faster, more accurate diagnostics ➢ Enhances patient outcomes & trust with visual
Slide 17: Strategic Expansion
Strategic Expansion Strategic Expansion
Slide 18: Expanding Strategically in Alignment with our Vision
Expanding Strategically in Alignment with our Vision Inorganic Expansion Strategy • Successfully acquired PH, Pune's largest B2C integrated diagnostic chain • This strategic acquisition seamlessly aligns East India Strategy with our commitment to providing top-notch healthcare services at affordable
Slide 19: Expansion Plans - Upcoming Hubs and Spokes Centres
Expansion Plans - Upcoming Hubs and Spokes Centres Tentative Timelines for Geography Count & Type H1 FY27 Commencement Hyderabad 5 Spokes H1 FY27 2 8 Hubs Spokes 2 Spokes H1 FY27 RoAPT H2 FY27 1 Hub H2 FY27 2 Hubs H1 FY27 Bengaluru 2 2 1 Hub H2 FY27 Hubs Spokes 2 Spokes H2 FY27 FY27 West Bengal Pune
Slide 20: Company Overview
Company Overview Strategic Expansion
Slide 21: Vijaya at a Glance
Vijaya at a Glance Vijaya Diagnostic is the largest integrated B2C focused diagnostic chain in India with 162 state-of-the-art centres spread across 27 cities & towns Evolved from a regional player to a player with presence in multiple geographies … … While retaining its core values of providing Qua
Slide 22: Our Journey
Our Journey 1981 1993 1995 2007 20032012 2005 2016 ▪ Vijaya Diagnostic Centre ▪ Became 1st independent diagnostic ▪ Recognized as one of the Best ▪ Received investment from incorporated in Hyderabad centre in South India to offer PET CT Imaging centres in Hyderabad Karakoram Limited & Kedaara from W
Slide 23: Integrated Diagnostics Player Offering One-Stop Solution
Integrated Diagnostics Player Offering One-Stop Solution Complete Range of Diagnostic Services under One Roof Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience 36.8 63.2 % Pathology (1) % Radiology (1) 22 1.
Slide 24: Dominant Position in Telangana & AP Markets with a Strong Brand Recall
Dominant Position in Telangana & AP Markets with a Strong Brand Recall Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets Present in Key Geographies of AP & Telangana 67 (1) % Hyderabad Revenue Contribution Nizamabad Man
Slide 25: Strong Traction observed in Newer Geographies (1/3)
Strong Traction observed in Newer Geographies (1/3) Differentiated offering has accelerated Vijaya’s success in new geographies West Bengal Network Greater Kolkata Area Network West Bengal Krishnanagar Greater Kolkata Area Diamond Harbour Faster break-even’s enable replication of densification strat
Slide 26: Strong Traction observed in Newer Geographies (2/3)
Strong Traction observed in Newer Geographies (2/3) Differentiated offering has accelerated Vijaya Brand’s success in new geographies Pune Network Pune Faster break-even’s enable replication of densification strategy in newer geographies 25 Existing Centre Upcoming Centres in H1 FY27
Slide 27: Strong Traction observed in Newer Geographies (3/3)
Strong Traction observed in Newer Geographies (3/3) Differentiated offering has accelerated Vijaya Brand’s success in new geographies Bengaluru Network Kalaburagi Bengaluru Faster break-even’s enable replication of densification strategy in newer geographies 26 Existing Centre Upcoming Centres in H1
Slide 28: Driving Geographical Diversification through Strategic Expansion
Driving Geographical Diversification through Strategic Expansion Gurgaon Hyderabad Pune RoAPT West Bengal Kalaburagi Bengaluru 69% 72% 68% 67% 20% 19% 20% 18% Geographical 6% 6% 6% 6% 7% 7% Revenue Mix 6% 4% Q4 FY26 Q3 FY26 FY26 FY25 Q4 FY26 Q3 FY26 FY26 FY25 Q4 FY26 Q3 FY26 FY26 FY25 Q4 FY26 Q3 FY2
Slide 29: Boosting Accessibility with Best-in-class Online Services & Home Collections
Boosting Accessibility with Best-in-class Online Services & Home Collections Online Services Home Collections Enhancing Customer Experience through Seamless Online App, E-Commerce Website and Call Centre Bookings Elevating Customer Experience through Home Collections Access to reports online & histo
Slide 30: Robust Technical Capabilities with State-of-the-art IT Infrastructure
Robust Technical Capabilities with State-of-the-art IT Infrastructure 40 9 Advanced Software to Manage Clinical Data CT Machines PET CT / Gamma machines 43 350+ MRI Machines Fully Integrated Radiology Radiologists, Lab Doctors & Advance Laboratory Information Systems (RIS) and Physicians Information
Slide 31: Experienced Board of Directors
Experienced Board of Directors Founder & Managing Director Executive Director Non-Executive Chairman & CEO Director Dr. S. Surendranath Ms. Suprita Reddy Mr. Sunil Chandra Ms. S Geeta Reddy Reddy Kondapally ✔ 40+ years of experience ✔ 22+ years of experience ✔ 22+ years of experience ✔ 35+ years of
Slide 32: Stellar Management Team
Stellar Management Team Founder & Chairman Managing Director & CEO Executive Director Dr. S. Surendranath Suprita Reddy Sunil Chandra Reddy Kondapally Chief Operating Officer Chief Financial Officer Chief Technology Officer Director - Laboratory Director - Radiology Sivaramaraju Ankit Shah Sai Prasa
Slide 33: Shareholding Pattern as at 31st March, 2026
Shareholding Pattern as at 31st March, 2026 Shareholding Pattern as at 31st March, 2026 Others 4.1% FIIs 13.3% Promoter & Promoter Group 52.6% DIIs 30.0% DIIs: Mutual Funds, AIFs and QIBs FIIs: Hedge Funds, Sovereign Wealth Funds, Foreign MFs, Pension Funds, Trusts and AMCs Others: Retail, Bodies Co
Slide 34: Doctors Connect Program in Q4 FY26
Doctors Connect Program in Q4 FY26 33
Slide 35: Awards & Accolades
Awards & Accolades Icon in Integrated Diagnostic Best Diagnostic Centre Icon in Integrated Diagnostic Most Trusted Brand of India Services by Times Health awarded at HMTV Healthcare Services by Times Health 2024-25 awarded by Best Healthcare Brands’ 2025 Excellence TS & AP 2025 Awards 2025 Excellenc
Slide 36: Annexure
Annexure Strategic Expansion
Slide 37: State-of-the-art Infrastructure (1/3)
State-of-the-art Infrastructure (1/3) 36
Slide 38: State-of-the-art Infrastructure (2/3)
State-of-the-art Infrastructure (2/3) 37
Slide 39: State-of-the-art Infrastructure (3/3)
State-of-the-art Infrastructure (3/3) 38
Slide 40: Advanced Equipment in Place to Deliver High Quality Services (1/2)
Advanced Equipment in Place to Deliver High Quality Services (1/2) 39
Slide 41: Advanced Equipment in Place to Deliver High Quality Services (2/2)
Advanced Equipment in Place to Deliver High Quality Services (2/2) 40
Slide 42: Robust Operational Metrics
Robust Operational Metrics Diagnostic Centre (Nos) Footfalls (Mn) Tests Performed (Mn) 4.68 162 4.19 16.92 145 151 3.62 3.55 14.79 121 3.18 11.89 95 9.32 10.05 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Test per Footfall (Nos) Revenue per Test (INR) Revenue per Footfa
Slide 43: Consistent Financial Performance
Consistent Financial Performance (INR Mn) Revenue EBIDTA PAT Impact of Impact of Impact of COVID-19 8,142 COVID-19 3,369 COVID-19 1,730 6,814 2,732 1,438 5,478 2,209 1,097 1,188 4,624 4,592 2,037 1,820 846 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 EBIDTA Margin (%) P
Slide 44: Sustainable Cash Generation & Increasing Return Ratios
Sustainable Cash Generation & Increasing Return Ratios Surplus Cash (INR Mn) CFO (1) / EBIDTA (%) 2,869 90% 2,465 2,554 2,067 1,851 83% 82% 80% 78% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 RoCE Pre-Tax (2) (%) RoE (3) (%) 46% 27% 20% 20% 20% 26% 26% 17% 25% 25% FY22 FY23 FY24 FY25 FY26 FY22
Slide 45: Consolidated Profit & Loss Account
Consolidated Profit & Loss Account (INR Mn) Particulars FY22 FY23 FY24 FY25 FY26 Revenue from operations 4,624 4,592 5,478 6,814 8,142 Cost of materials consumed 715 589 654 848 947 Employee benefits expense 707 785 902 1,122 1,307 Other expenses 1,165 1,398 1,712 2,113 2,518 EBITDA 2,037 1,820 2,20
Slide 46: Consolidated Balance Sheet
Consolidated Balance Sheet (INR Mn) ASSETS Mar-22 Mar-23 Mar-24 Mar-25 Mar-26 EQUITY & LIABILITIES Mar-22 Mar-23 Mar-24 Mar-25 Mar-26 NON-CURRENT ASSETS 4,436 5,777 7,714 9,664 11,851 EQUITY 4,695 5,466 6,599 7,991 9,572 Property, plant and equipment 1,966 2,940 3,785 4,469 5,625 Equity share capita
Slide 47: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (INR Mn) Particulars Mar-22 Mar-23 Mar-24 Mar-25 Mar-26 Cash Flow from Operating Activities Profit before Tax 1,474 1,135 1,587 1,932 2,327 Adjustment for Non-Operating Items 572 683 599 786 1,070 Operating Profit before Working Capital Changes 2,046 1,818 2,186 2,71
Slide 48: Thank You
Thank You For further information please contact: Mr. Dhiren Gala AGM - Strategy & Investor Relations +91 90598 93206 dhiren.g@vijayadiagnostic.in ir@vijayadiagnostic.in www.vijayadiagnostic.com Corporate Office : #6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana
Vijaya Diagnostic Centre — Q4 FY26 Earnings Presentation on 6ix